Trial · NCT06091956
A Study of Deucravacitinib to Treat LPP and FFA
NCT06091956, Phase 2, Completed, Mayo Clinic; results first posted 2025-06-08
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Study of Deucravacitinib to Treat LPP and FFA. Trials, record NCT06091956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06091956
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Deucravacitinib to Treat LPP and FFA
- NCT number
- NCT06091956
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Lichen Planopilaris
- Interventions
- Deucravacitinib
- First posted
- 2023-10-23
- Last updated
- 2025-06-08
- Results first posted
- 2025-06-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score | 24 weeks | Number of subjects to have complete or partial response to Deucravacitinib treatment as measured by Lichen Planopilaris Activity Index (LPPAI) score: complete response = LPPAI reduction greater than 85% from baseline score and partial response = LPPAI reduction between 25-85% from baseline score. LPPAI scores range from 0 (no disease) to 10 (most severe) with higher scores indicating worsening disease. |
| Secondary | Response to Deucravacitinib Measured by Physician Global Assessment (PGA) Score | Baseline, 24 weeks | Number of subjects to have an overall response to treatment (Deucravacitinib) as assessed by the physician using PGA. PGA scores range from 0 to 6 with scores between 0-3 indicating a response to treatment. |
| Secondary | Change in the Dermatology-LQI Score | Baseline, 24 weeks | Measured by the Dermatology Life Quality Index (DLQI) questionnaire that asks participants to measure their Lichen Planopilaris (LLP) or Frontal Fibrosing Alopecia (FFA) has affected their life over the last month. 10-item questionnaire using a scale of 0 (not at all) to 3 (very much). Maximum score is 30 and minimum score is 0, with higher scores indicating worsening quality of life. |
| Secondary | Change in Pruritus Visual Analogue Scale (VAS) | Baseline, 24 weeks | Subjects are asked on average and at its worst to rate their itch level over the past day by placing a vertical mark on the line with one end indicating no itch and the other end indicating worst imaginable itch. That point will be measured from the "No itch" end, and the number of centimeters (cm) will be reported as the pain score. VAS score interpretation: VAS 0 cm = No itch; VAS \<3 cm = Mild itch; VAS ≥3 cm \<7 cm = Moderate itch; VAS ≥7 cm \<9 cm = Severe itch, VAS ≥9 cm \<10 cm = Very severe itch. |
| Secondary | Change in Pruritus Verbal Rating Scale (VRS) | Baseline, 24 weeks | Subjects are asked on average and at its worst to rate their itch in the last 24 hours using a scale of 0= none, 1-mild, 2=moderate, 3= severe. Scores range from 0-3, with higher scores indicating worsening itch. |
| Secondary | Change in Numerical Rating Scale (NRS) for Itch | Baseline, 24 weeks | Itch is measured using numerical rating scale 0-10; 0= no itch, 1-4 = mild itch, 4-7 = moderate itch, 7-9 = severe itch, 10= very severe itch |
| Secondary | Change in Skindex-16 | Baseline, 24 weeks | Measured by the Skindex-16 scoring system focused on itch and its impact upon quality of life. 16-item questionnaire using a scale of 0=never bothered to 6=always bothered, total score 0 to 96 with higher score indicated worse quality of life. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score | 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Response to Deucravacitinib Measured by Physician Global Assessment (PGA) Score | Baseline, 24 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change in the Dermatology-LQI Score | Baseline, 24 weeks | ITT analysis; includes a total of 10 subjects, 9 who completed the study and 1 who completed through week 16. | score on a scale | MEAN |
| SECONDARY | Change in Pruritus Visual Analogue Scale (VAS) | Baseline, 24 weeks | ITT analysis; includes a total of 10 subjects, 9 who completed the study and 1 who completed through week 16. | units on a scale | MEAN |
| SECONDARY | Change in Pruritus Verbal Rating Scale (VRS) | Baseline, 24 weeks | ITT analysis; includes a total of 10 subjects, 9 who completed the study and 1 who completed through week 16. | score on a scale | MEAN |
| SECONDARY | Change in Numerical Rating Scale (NRS) for Itch | Baseline, 24 weeks | ITT analysis; includes a total of 10 subjects, 9 who completed the study and 1 who completed through week 16. | score on a scale | MEAN |
| SECONDARY | Change in Skindex-16 | Baseline, 24 weeks | ITT analysis; includes a total of 10 subjects, 9 who completed the study and 1 who completed through week 16. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete and Partial Response to Deucravacitinib Measured by Lichen Planopilaris Activity Index (LPPAI) Score | Deucravacitinib Treatment for Lichen Planopilaris | 9 | Participants | ||
| Response to Deucravacitinib Measured by Physician Global Assessment (PGA) Score | Deucravacitinib Treatment for Lichen Planopilaris | 8 | Participants | ||
| Change in the Dermatology-LQI Score | Deucravacitinib Treatment for Lichen Planopilaris | 0.0 | Standard Deviation 4.2 | score on a scale | |
| Change in Pruritus Visual Analogue Scale (VAS) | Deucravacitinib Treatment for Lichen Planopilaris | Itch Level on Average | -1.6 | Standard Deviation 3.0 | units on a scale |
| Change in Pruritus Visual Analogue Scale (VAS) | Deucravacitinib Treatment for Lichen Planopilaris | Itch Level at its Worst | -2.7 | Standard Deviation 3.8 | units on a scale |
| Change in Pruritus Verbal Rating Scale (VRS) | Deucravacitinib Treatment for Lichen Planopilaris | Itch level on average | -0.9 | Standard Deviation 0.7 | score on a scale |
| Change in Pruritus Verbal Rating Scale (VRS) | Deucravacitinib Treatment for Lichen Planopilaris | Itch level at its worst | -0.9 | Standard Deviation 0.6 | score on a scale |
| Change in Numerical Rating Scale (NRS) for Itch | Deucravacitinib Treatment for Lichen Planopilaris | -1.9 | Standard Deviation 3.3 | score on a scale | |
| Change in Skindex-16 | Deucravacitinib Treatment for Lichen Planopilaris | -21.0 | Standard Deviation 22.1 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Deucravacitinib Treatment for Lichen Planopilaris | 11 | |
| Overall Study | COMPLETED | Deucravacitinib Treatment for Lichen Planopilaris | 9 | |
| Overall Study | NOT COMPLETED | Deucravacitinib Treatment for Lichen Planopilaris | 2 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acne | Skin and subcutaneous tissue disorders | Deucravacitinib Treatment for Lichen Planopilaris | 9 | 11 | 9 |
| other | Hand Dermatitis | Skin and subcutaneous tissue disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Rash | Skin and subcutaneous tissue disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Rash/Acne | Infections and infestations | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Virus (cold/flu) | General disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Headache | Nervous system disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 2 |
| other | Bakers Cyst | Musculoskeletal and connective tissue disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Canker Sore and Mouth Tenderness | Gastrointestinal disorders | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
| other | Canker Sores on Tongue | Gastrointestinal disorders | Deucravacitinib Treatment for Lichen Planopilaris | 2 | 11 | 2 |
| other | Upper Respiratory Infection | Infections and infestations | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 | 1 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Deucravacitinib Treatment for Lichen Planopilaris | 0 | 11 |
| Total, other adverse events | Deucravacitinib Treatment for Lichen Planopilaris | 11 | 11 |
| Total, serious adverse events | Deucravacitinib Treatment for Lichen Planopilaris | 1 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06091956
GET https://conductscience.org/api/trials/v1/NCT06091956/events?page=2